Dendritic cell composition
AssigneesMedigene Immunotherapies GmbH, Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
InventorsSlavoljub Milosevic, Christian Ellinger, Carina Wehner, Dolores Schendel
Life of this patent
Estimating the term…
Abstract
The present invention contemplates dendritic cell compositions. The dentritic cell compositions employ MHC class-II targeting signals fused to an antigen or fragment thereof to obtain MHC II presentation of the antigen or fragment thereof. In particular, the invention refers to a dendritic cell vaccine comprising dendritic cells expressing a MHC class-II targeting signal fused to an antigen or fragment thereof. Dendritic cell vaccines for the stimulation of an immune response against melanoma-associated antigen are also described.
Claims15
A dendritic cell composition comprising
- A) dendritic cells that express at least one fusion protein, wherein said fusion protein comprises:
- i) at least one antigen or a fragment thereof;
- and
- ii) at least one targeting signal sequence, wherein said targeting signal sequence comprises:
- a) an endoplasmatic reticulum (ER)-translocation signal sequence preceding the N-terminus of the antigen or fragment thereof;
- and
- b) a transmembrane and cytoplasmic domain comprising an endosomal/lysosomal targeting sequence following the C-terminus of the antigen or fragment thereof;
- wherein the targeting signal sequence of a) or b) promotes MHC II presentation of the antigen or fragment thereof;
- and
- B) dendritic cells that express at least one antigen or a fragment thereof, wherein the antigen or fragment thereof is not fused to a targeting signal sequence that promotes MHC II presentation of the antigen or fragment thereof;
- and
- wherein the antigen of A and the antigen of B are the same antigen.
Dependencies are inferred from the claim text.